Provided by Tiger Trade Technology Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.058
+0.0023.57%
Volume:11.59M
Turnover:686.01K
Market Cap:184.59M
PE:-11.73
High:0.062
Open:0.055
Low:0.055
Close:0.056
52wk High:0.065
52wk Low:0.019
Shares:3.18B
Float Shares:2.61B
Volume Ratio:4.81
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.005
EPS(LYR):-0.005
ROE:-77.47%
ROA:-41.91%
PB:10.07
PE(LYR):-11.73

Loading ...

Company Profile

Company Name:
ACTINOGEN MEDICAL LTD
Exchange:
ASX
Establishment Date:
1999
Employees:
6
Office Location:
109 Pitt Street,Suite 901, Level 9,Sydney,New South Wales,Australia
Zip Code:
2000
Fax:
61 2 8964 7588
Introduction:
Actinogen Medical Limited, a biotechnology company, develops treatments for Alzheimer's disease, and the cognitive deficiency associated with other neurological and metabolic diseases in Australia. It is developing Xanamem, a therapy for Alzheimer's disease; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. The company is also developing XanaHES, a Phase I, single blinded, central reader blinded, placebo-controlled, dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited is based in Sydney, Australia.